Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Livzon Pharmaceutical Group Inc. (000513.SZ)
Zhuhai, CN
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.87% | -0.48% | -6.00% | -12.92% | -13.19% | -10.45% | -14.73% | -21.62% | -37.97% | +63.11% | +1,253.51% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.8% Q1'26: -9.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+1.3% Q1'26: -8.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+18.2% Q1'26: +25.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.0% ★ Q1'26: +28.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+25.4% ★ Q1'26: +28.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-2.9% ★ Q1'26: -1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.21× ★ Q1'26: 1.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.62B
est: 6.53B (+1.4%)
|
7.65B
est: 7.85B (-2.6%)
|
8.53B
est: 8.74B (-2.4%)
|
8.86B
est: 9.11B (-2.7%)
|
9.38B
est: 9.70B (-3.3%)
|
10.52B
est: 10.62B (-0.9%)
|
12.06B
est: 11.82B (+2.1%)
|
12.63B
est: 12.75B (-1.0%)
|
12.43B
est: 12.88B (-3.5%)
|
11.81B
est: 11.81B (+0.0%)
|
11.91B
est: 12.16B (-2.1%)
|
12.19B
11.86B – 12.52B
+0.3% YoY
|
12.76B
11.47B – 13.59B
+4.6% YoY
|
13.30B
12.42B – 13.92B
+4.2% YoY
|
| EBITDA |
1.09B
est: 1.45B (-24.8%)
|
1.29B
est: 1.74B (-25.8%)
|
1.45B
est: 1.94B (-25.0%)
|
1.36B
est: 2.02B (-32.5%)
|
1.76B
est: 2.15B (-18.3%)
|
2.42B
est: 2.36B (+2.8%)
|
2.34B
est: 2.62B (-10.6%)
|
2.56B
est: 2.83B (-9.4%)
|
2.74B
est: 2.86B (-4.1%)
|
3.09B
est: 4.23B (-27.0%)
|
3.18B
est: 4.35B (-27.0%)
|
4.36B
4.24B – 4.48B
+0.3% YoY
|
4.56B
4.10B – 4.86B
+4.6% YoY
|
4.76B
4.44B – 4.98B
+4.2% YoY
|
| EBIT |
777.88M
est: 1.14B (-31.8%)
|
930.43M
est: 1.37B (-32.2%)
|
1.10B
est: 1.53B (-28.3%)
|
1.00B
est: 1.59B (-37.2%)
|
1.37B
est: 1.70B (-19.0%)
|
2.03B
est: 1.86B (+9.3%)
|
1.92B
est: 2.07B (-7.2%)
|
1.93B
est: 2.23B (-13.3%)
|
1.92B
est: 2.25B (-14.7%)
|
2.54B
est: 3.59B (-29.4%)
|
2.62B
est: 3.70B (-29.0%)
|
3.71B
3.61B – 3.81B
+0.3% YoY
|
3.88B
3.49B – 4.13B
+4.6% YoY
|
4.04B
3.78B – 4.23B
+4.2% YoY
|
| Net Income |
622.64M
est: 641.32M (-2.9%)
|
784.35M
est: 769.52M (+1.9%)
|
4.43B
est: 4.36B (+1.7%)
|
1.08B
est: 1.07B (+0.7%)
|
1.30B
est: 1.27B (+2.7%)
|
1.71B
est: 1.66B (+3.5%)
|
1.78B
est: 1.89B (-5.8%)
|
1.91B
est: 1.84B (+3.6%)
|
1.95B
est: 1.99B (-1.6%)
|
2.06B
est: 1.96B (+5.1%)
|
2.02B
est: 2.15B (-6.0%)
|
2.10B
2.06B – 2.14B
-2.2% YoY
|
2.31B
2.00B – 2.70B
+9.7% YoY
|
2.58B
2.36B – 2.74B
+11.7% YoY
|
| SGA |
3.13B
est: 2.30B (+36.0%)
|
3.79B
est: 2.77B (+37.1%)
|
3.77B
est: 3.08B (+22.5%)
|
3.81B
est: 3.21B (+18.8%)
|
3.72B
est: 3.42B (+8.9%)
|
3.74B
est: 3.74B (0.0%)
|
4.55B
est: 4.16B (+9.2%)
|
4.54B
est: 4.49B (+1.1%)
|
4.25B
est: 4.54B (-6.3%)
|
3.87B
est: 4.13B (-6.5%)
|
4.10B
est: 4.26B (-3.8%)
|
4.27B
4.15B – 4.38B
+0.3% YoY
|
4.47B
4.01B – 4.76B
+4.6% YoY
|
4.65B
4.35B – 4.87B
+4.2% YoY
|
| EPS |
0.74
est: 0.70 (+6.2%)
|
0.90
est: 0.84 (+7.6%)
|
4.78
est: 4.73 (+1.0%)
|
1.16
est: 1.17 (-0.6%)
|
1.39
est: 1.38 (+0.8%)
|
1.83
est: 1.80 (+1.6%)
|
1.90
est: 2.05 (-7.3%)
|
2.04
est: 2.00 (+1.8%)
|
2.10
est: 2.16 (-2.7%)
|
2.24
est: 2.20 (+2.0%)
|
2.27
est: 2.41 (-5.8%)
|
2.35
2.31 – 2.40
-2.2% YoY
|
2.58
2.24 – 3.02
+9.7% YoY
|
2.89
2.64 – 3.06
+11.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.12% | 897.0K | 0.68% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.09% | 34.6K | 0.65% |
| 3 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.08% | 292.4K | 0.44% |
| 4 | State Street SPDR S&P China ETF GXC | 0.03% | 124.6K | 0.59% |
| 5 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.03% | 21.0K | 0.55% |
| 6 | HSBC Asia Pacific Ex Japan Screened Equity UCITS ETF HSXD.L | 0.01% | 87.8K | 0.25% |
| 7 | HSBC Emerging Market Screened Equity UCITS ETF HSEM.L | 0.01% | 36.1K | 0.18% |
| 8 | Franklin FTSE China ETF FLCH | 0.01% | 29.5K | 0.19% |
| 9 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 136.4K | 0.19% |
| 10 | iShares Emerging Markets Equity Factor ETF EMGF | 0.01% | 138.5K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yanggang Tang | Executive Vice Chairman | 6M | male |
| Xiao Xu | Vice President | 6M | male |
| Yuxuan Huang | Vice President | 6M | female |
| Jun Du | Vice President | 6M | male |
| Daping Liu | President | 5M | male |
| Liu Ning | Company Secretary & Secretary to the Board | 3M | female |
| Maolin Wang | GM of Legal & Compliance | 405.8K | male |
| Yongmei Ran | Employee Representative Director & Assistant to the President | 116.5K | female |
| Sheng Wang | Financial Controller, Head of Accounting Department & CFO | — | male |
| Jianying Zhuang | Head of Accounting Department | — | female |
| Jianing Liu | Chief Investment Officer & Head of BD Dept. | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000513.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
